Question 1

How is Thymalin different from Thymosin Alpha-1?

Accepted Answer

Thymosin Alpha-1 is a single, defined 28-amino-acid peptide with known sequence and receptor interactions. Thymalin is a crude polypeptide extract containing many peptide fragments. TA-1 has international regulatory approvals and more rigorous clinical data. Thymalin has longer clinical history in Russia but is a less standardized product.

Question 2

Is Thymalin approved anywhere?

Accepted Answer

Yes. Thymalin has been approved for clinical use in Russia since the 1980s for immune deficiency states, post-surgical recovery, and chronic infections. It is not approved in the US, EU, or Australia.

Question 3

Can Thymalin reduce aging-related mortality?

Accepted Answer

One longitudinal study from Khavinson's institute showed reduced mortality in elderly patients over 15 years. This is intriguing but comes from a single research group, lacks randomization, and has not been replicated. It should be interpreted as hypothesis-generating rather than conclusive.

Question 4

Is Thymalin safe?

Accepted Answer

Decades of clinical use in Russia have produced a favorable safety profile. Reported adverse effects are minimal — primarily injection-site reactions and occasional mild allergic responses to animal-derived protein. As with any animal extract, theoretical prion contamination risk exists, though no cases have been reported.

Question 5

Should I use Thymalin or its synthetic analog Vilon?

Accepted Answer

Vilon (KE dipeptide) offers standardization, oral dosing, and no animal-derived contamination risk. Thymalin offers the full polypeptide complex with longer clinical history. Purists in the bioregulator community often prefer the original extract; pragmatists prefer the synthetic analog.

Question 6

What is the difference between Thymalin and Thymosin Alpha-1?

Accepted Answer

Thymalin is a crude polypeptide extract from calf thymus containing dozens of uncharacterized peptide fragments, while Thymosin Alpha-1 (TA-1) is a single, well-defined 28-amino-acid peptide with a known sequence (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN). TA-1 has undergone rigorous clinical development and holds regulatory approval in over 35 countries for hepatitis B and as an immune adjuvant. Thymalin has clinical approval only in Russia and CIS countries. From a mechanistic standpoint, TA-1 acts primarily through TLR9 and TLR2 signaling to activate dendritic cells and NK cells, while Thymalin's multiple peptide components likely engage several immune pathways simultaneously but with less precision.

Question 7

How does Thymalin support immune function in aging?

Accepted Answer

The thymus gland undergoes progressive involution with age, shrinking significantly by middle age and producing fewer naive T-cells. Thymalin's polypeptide complex is proposed to compensate for this decline by providing exogenous thymic signaling molecules that promote T-cell differentiation and maturation. In Khavinson's published studies, elderly patients receiving Thymalin showed normalization of CD4/CD8 T-cell ratios, increased natural killer cell activity, and improved lymphocyte proliferative responses to mitogens. The landmark 15-year follow-up study reported that Thymalin combined with Epithalamin reduced mortality in elderly cohorts, suggesting that restoring thymic function may have systemic anti-aging benefits beyond immune markers alone.

Question 8

Can Thymalin help with recurrent infections?

Accepted Answer

Thymalin has been used clinically in Russia specifically for patients with recurrent respiratory and urogenital infections associated with secondary immunodeficiency. Published Russian clinical data report reduced infection frequency and severity in patients treated with standard 10-day Thymalin courses, particularly those with documented T-cell deficiencies. The proposed mechanism involves restoring T-cell numbers and function to adequate levels for effective pathogen clearance. However, these studies generally lack the blinding, randomization, and sample sizes expected by Western regulatory agencies, so the evidence should be considered preliminary rather than definitive.

Question 9

What is the typical Thymalin treatment course?

Accepted Answer

The standard Thymalin protocol approved in Russian clinical practice consists of 10 mg administered via intramuscular injection once daily for 5 to 10 consecutive days. This course is typically repeated one to two times per year for ongoing immune maintenance, with some practitioners recommending seasonal administration before winter flu season. The lyophilized powder is reconstituted with sterile sodium chloride solution immediately before injection. For elderly patients in Khavinson's longevity protocols, courses were administered annually in combination with Epithalamin (pineal extract) over periods spanning many years.

Origin / Manufacturer	Animal-derived (calf thymus extract)
Active Components	Thymus polypeptide complexSodium chloride (for injection)
Storage	2–8°C refrigerated
Shelf Life	24 months
Form Factor	Lyophilized powder for injection (10 mg vial)

Thymalin (Thymic Polypeptide Complex)

Specifications

Clinical Evidence

Frequently Asked Questions

Related Peptides

Epitalon

Thymosin α1

Thymulin

Vilon